Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients

Cell Immunol. 2012 Mar-Apr;276(1-2):110-3. doi: 10.1016/j.cellimm.2012.04.009. Epub 2012 Apr 21.

Abstract

In hepatitis C infection, the production of inappropriate cytokines levels may contribute to viral persistence and may affect the response to antiviral therapy. We investigate the effect of IL4 C-590T and C-33T polymorphisms on the response to combination therapy with interferon and ribavirin in chronic HCV patients. These single nucleotide polymorphisms were determined by PCR-RFLP in 235 responder and 210 non-responder to combination therapy. The IL4-590 T/T and -33 T/T genotypes were associated with resistance to the therapy (p<0.001, p=0.001 respectively). Haplotypes T(-590) T(-33) and T(-590) C(-33) were associated with a higher risk in non-responder patients than the responders (p<0.001 for each) while frequency of haplotype C(-590) C(-33) (with all wild alleles) was significantly higher in responders as compared to non-responders (p<0.001). These results suggest that inheritance of the IL4 polymorphisms may be associated with resistance to combined antiviral therapy in Egyptian HCV patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antiviral Agents / therapeutic use
  • Drug Combinations
  • Egypt
  • Female
  • Genetics, Population
  • Genotype
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / genetics*
  • Humans
  • Interferons / therapeutic use
  • Interleukin-4 / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Drug Combinations
  • IL4 protein, human
  • Interleukin-4
  • Ribavirin
  • Interferons